The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats

Pharmacology and Toxicology

Volumn 78, Issue 1, 1996, Pages 44-49

  Larson, J L ^a   Pino, M V ^a   Geiger, L E ^a   Simeone, C R ^a  

^a Rhone Poulenc Rorer Central Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM;

ABDOMINAL DISTENSION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERITIS; ARTICLE; ATAXIA; CARDIOTOXICITY; CONTROLLED STUDY; DEATH; FEMALE; GASTROINTESTINAL TOXICITY; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HISTOPATHOLOGY; HYPERSALIVATION; MICROSCOPY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STOMACH INJURY; SUBLINGUAL GLAND; TOXICITY;

EID: 0030053450     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1996.tb00178.x     Document Type: Article

References (21)

1. Alousi, A., R. J. Fabian, J. F. Baker & R. M. Stroshane: Milrinone. In: New drugs annual: Cardiovascular drugs. Ed.: A. Scriabine Raven Press, New York 1985, Vol. 3, pp. 245–283.
2. Collins, J. J., M. R. Elwell, J. C. Lamb IV, A. G. Manus, J. E. Heath & G. T. Makovec: Subchronic toxicity of orally administered (gavage and dosed‐feed) theophylline in Fischer 344 rats and B6CF1 mice. Fundam. Appl. Toxicol. 1988, 11, 472–484.
3. Eckmann, F., K. Fichte, U. Meya & M. Sastre‐Hernandez: Rolipram in major depression: results of a double‐blind comparative study with amitriptyline. Curr. Ther. Res. 1988, 43, 291–295.
4. Genain, C. P., T. Roberts, R. L. Davis, M.‐H. Nguyen, A. Uccelli, D. Faulds, Y. Li, J. Hedgpeth & S. L. Hauser: Prevention of autoimmune demyelination in non‐human primates by a cAMP‐specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. 1995, 92, 3601–3605.
5. Harleman, J. H., E. C. Joseph, R. J. Eden. T. F. Walker, I. R. Major & M. S. Lamb: Cardiotoxicity of a new inotrope/vasodilator drug (SK&F 94120) in the dog. Arch. Toxicol. 1986, 59, 51–55.
6. Horowski, R. & M. Sastre‐Hernandez: Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr. Therap. Res. 1985, 38, 23–29.
7. Johansson, S.: Cardiovascular lesions in Sprague‐Dawley rats induced by long‐term treatment with caffeine. Acta Pathol. Microbiol. Immunol. Scand. [A] 1981, 89, 185–191.
8. Kerns, W. D., E. Arena & D. G. Morgan: Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat. Amer. J. Pathol. 1989, 135, 339–349.
9. Physicians' Desk References®, 1995, 49th Edition, Medical Economics, Montvale, NJ, U.S.A.
10. Przegalinski, E., K. Bigajska & A. Lewandowska: The influence of rolipram on the central serotoninergic system. Pharmacopsvchiat. 1981, 14, 162–166.
11. Sandusky, G. E. & J. R. Means: Acute and subchronic toxicology of LY‐195115 in rats and dogs. Toxicol. Lett. 1987, 38, 177–186.
12. Sandusky, G. E., R. B. Franklin & J. R. Means: Acute, subchronic, and chronic toxicity of the cardiotonic isomazole in rats. Fundam. Appl. Toxicol. 1989, 13, 409–417.
13. Sandusky, G. E., M. J. Vodienik & R. N. Tamura: Cardiovascular and adrenal proliferative lesions in Fischer 344 rats induced by long‐term treatment with Type III phosphodiesterase inhibitors (positive inotropic agents), isomazole and indolidan. Fundam. Appl. Toxicol. 1991, 16, 198–209.
14. Sandusky, G. E., J. R. Means & H. K. Yeager: Coronary artery toxicity in beagle dogs given indolan, a type III phosphodiesterase inhibitor. Fundam. Appl. Toxicol. 1993, 21, 228–235.
15. Sheppard, H., G. Wiggan & W. H. Tsien: Structure‐activity relationship for inhibitors of phosphodiesterase from erythrocytes and other tissues. Adv. Cycl. Nucl. Res. 1971, 1, 103–112.
16. Torphy, T. J. & B. J. Undem: Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991, 46, 512–523.
17. Wachtel, H.: Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′‐monophosphate phosphodiesterase inhibitors. Psychophannacology 1982, 77, 309–316.
18. Weishaar, R. E.: Multiple molecular forms of phosphodiesterase: an overview. J. Cycl. Nucl. Prut. Res. 1987, 11, 463–472.
19. Westwood, F. R., T. J. Iswaran & P. Greaves: Pathologic changes in blood vessels following administration of an inotropic vasodilator (ICI 153, 110) to the rat. Fundam. Appl. Toxicol. 1990, 14, 797–809.
20. Westwood, F. R., T. J. Iswaran & P. Greaves: Long‐term effects of an inotropic phosphodiesterase inhibitor (ICI 153,110) on the rat salivary gland, Harderian gland, and intestinal mucosa. Toxicol. Pathol. 1991, 19, 214–223.
21. Zeller, E., H. J. Stief, B. Pflug & M. Sastre‐Hernandez: Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984, 17, 188–190.